Sign in Subscribe
Cancer research

Ovarian Cancer Research Reveals Insights into Estrogen and Progesterone Receptor Expression

Strategic Insights

— 1 min read

Researchers at Johann Wolfgang Goethe University have conducted a study on the epidemiological and in vitro studies of epithelial ovarian cancer (OC), shedding light on the link between hormone receptor (HR) expression, tumorigenesis, and survival. The study aimed to examine the expression patterns of estrogen- and progesterone receptors (ER and PR) in OC across different histological subtypes and assess their prognostic value in disease progression. The analysis of data from 164 patients who received primary treatment at University Hospital Frankfurt between January 1999 and December 2019 revealed significant correlations between ER and PR expression and histological subtypes.

Key Takeaways:

  • The study found a link between hormone receptor expression and tumorigenesis in ovarian cancer, suggesting that antihormonal therapies may be effective in treating the disease.
  • Strong ER and PR expression was more common in high-grade serous carcinoma, low-grade serous carcinoma, and endometrioid carcinoma, while low PR expression was linked to higher tumor grading.
  • Notably, clear cell carcinoma patients with weak PR expression had better survival rates than those with strong PR expression.
  • The difference in overall survival (OS) between ER-positive and ER-negative patients was minimal, but median progression-free survival (PFS) and OS were slightly better in cases with weak PR expression.
  • The study highlights the importance of considering the expression patterns and associated prognosis of ER and PR in different histological subtypes and clinical factors when treating ovarian cancer.

Statistics:

  • The study analyzed data from 164 patients who received primary treatment at University Hospital Frankfurt between January 1999 and December 2019.
  • Strong ER expression was found in 55% of high-grade serous carcinoma, 43% of low-grade serous carcinoma, and 42% of endometrioid carcinoma patients.
  • Weak PR expression was observed in 22% of clear cell carcinoma patients with better survival rates compared to those with strong PR expression.
  • Median PFS was 24 months in cases with weak PR expression, compared to 19 months in those with strong PR expression (p = 0.797).
  • Median OS was 58 months in cases with weak PR expression, compared to 53 months in those with strong PR expression (p = 0.45).

Sources:

  • Johann Wolfgang Goethe University, Dept. of Obstetrics and Gynecology, Frankfurt, Germany
  • Prognostic Impact of Estrogen and Progesterone Receptor Expression across Histological Subtypes and Clinical Factors in Epithelial Ovarian Cancer, Gynecologic and Obstetric Investigation, 2025:1-15.
  • Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland (www.karger.com/; content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223845)

Read more